Insights - Synergy Pharmaceuticals (SGYP) is getting some much-needed love with phase 2 data for the company's lead drug candidate, plecanatide in Irritable Bowel Syndrome (IBS-C).
Read NowInsights - Illumina (ILMN) yet again posted great quarterly numbers, surpassing consensus on revenue and earnings.
Read NowInsights - NewLink (NLNK) and Roche (RHHBY) will collaborate on the development of new IDO inhibitors, and combinations with NLNK's NLG919.
Read NowInsights - In last week’s biotech recap, and again at PropThink.com this week, we outlined some key support levels for the S&P 500 (SPX or SPY), explaining … Continue Reading
Read NowInsights - FDA put the breaks on Repros (RPRX) on Friday when it indicated that an upcoming meeting would not be the pre-NDA meeting investors expected.
Read NowInsights - Tekmira (TKMR) revealed the first data for TKM-HBV publicly on Wednesday at a medical conference. Though early, Mr. Fink likes what he sees.
Read NowInsights - Multiple reasons for support, 1800 on the SPX/SPY is an interesting level to watch. No, it's not time to panic.
Read Now
